((自动化翻译由路透提供，请见免责声明 ))
10月16日 - ** Arcellx 股价在午后交易中上涨约 2.5%，报 92 美元
** 券商Guggenheim将ACLX的预测价格从77美元上调至105美元，维持 "买入 "评级
** 券商继续看好 ACLX 的主导产品 anito-cel，认为它是治疗一种名为多发性骨髓瘤的血癌的最佳疗法。
** Anito-cel是一种CAR-T疗法，它利用患者经过改造的T细胞来抗癌，目前正在对复发或停止治疗的多发性骨髓瘤进行测试。
** ACLX 计划在 12 月提交 anito-cel 中期试验的初步数据
** 券商称，投资者预计初步数据将显示anito-cel的疗效优于强生-联想生物技术公司的Carvykti
** 包括本交易日的涨幅在内，该股今年以来的涨幅约为 66
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.